Risperidone alone or in combination for acute mania

Rendell JM, Gijsman HJ, Bauer MS, Goodwin G, Geddes J

Published Online:

January 21, 2009

This review included six trials and investigated the efficacy and tolerability of risperidone, an atypical antipsychotic, as treatment for mania compared to placebo or other medicines. High withdrawal rates from the trials limit the confidence that can be placed on the results. Risperidone, both as monotherapy and combined with lithium, or an anticonvulsant, was more effective at reducing manic symptoms than placebo but caused more weight gain, sedation and elevation of prolactin levels. The efficacy of risperidone was comparable to that of haloperidol both as monotherapy and as adjunctive treatments to lithium, or an anticonvulsant. Risperidone caused less movement disorders than haloperidol but there was some evidence for greater weight gain.

Abstract (click to read)

Background:

Risperidone, an atypical antipsychotic, is used to treat mania both alone and in combination with other medicines.

Objectives:

To review the efficacy and tolerability of risperidone as treatment for mania.

Search strategy:

The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies December 2004), The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL and PsycINFO were searched in December 2004. Reference lists and English language textbooks were searched; researchers in the field and Janssen-Cilag were contacted.

Selection criteria:

Randomised controlled trials comparing risperidone with placebo or other drugs in acute manic or mixed episodes.

Data collection and analysis:

Two reviewers independently extracted data from trial reports. Janssen-Cilag was asked to provide missing information.

Quality assessment
As in other trials of treatment for mania, the high proportion of imputed efficacy data resulting from rates of failure to complete treatment of between 12% and 62% may have biased the results.

Main results:

Six trials (1343 participants) of risperidone as monotherapy or as adjunctive treatment to lithium, or an anticonvulsant, were identified. Permitted doses were consistent
with those recommended by the manufacturers of Haldol (haloperidol) and Risperdal (risperidone) for treatment of mania and trials involving haloperidol allowed antiparkinsonian treatment. Risperidone monotherapy was more effective than placebo in reducing manic symptoms, using the Young Mania Rating Scale (YMRS) (weighted mean difference (WMD) -5.75, 95% confidence interval (CI) -7.46 to -4.04, P<0.00001; 2 trials) and in leading to response, remission and sustained remission. Effect sizes for monotherapy and adjunctive treatment comparisons were similar. Low levels of baseline depression precluded reliable assessment of efficacy for treatment of depressive symptoms. Risperidone as monotherapy and as adjunctive treatment was more acceptable than placebo, with lower incidence of failure to complete treatment (RR 0.66, 95% CI 0.52 to 0.82, P = 0.0003; 5 trials). Overall risperidone caused more weight gain, extrapyramidal disorder, sedation and increase in prolactin level than placebo.

There was no evidence of a difference in efficacy between risperidone and haloperidol either as monotherapy or as adjunctive treatment. The acceptability of risperidone and haloperidol in incidence of failure to complete treatment was comparable. Overall risperidone caused more weight gain than haloperidol but less extrapyramidal disorder and comparable sedation.

Authors' conclusions:

Risperidone, as monotherapy and adjunctive treatment, is effective in reducing manic symptoms. The main adverse effects are weight gain, extrapyramidal effects and sedation. Risperidone is comparable in efficacy to haloperidol.

Higher quality trials are required to provide more reliable and precise estimates of its costs and benefits.

This record should be cited as:

Rendell JM, Gijsman HJ, Bauer MS, Goodwin G, Geddes J. Risperidone alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004043. DOI: 10.1002/14651858.CD004043.pub2

Assessed as up to date:

October 4, 2005

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Depression, Anxiety and Neurosis Group

Health topics:

Mental health > Bipolar disorder

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Risperidone alone or in combination for acute mania

More like this

Copyright © 2012 - The Cochrane Collaboration